Arla Foods Ingredients to Showcase High-Protein Concepts for GLP-1 Users

Arla Foods Ingredients has announced its participation in Vitafoods Europe 2026, where it will showcase innovative high-protein, nutrient-dense applications specifically designed for users of GLP-1 anti-obesity medications. The event is scheduled to take place in Barcelona from May 5 to 7.

GLP-1 receptor agonists, initially developed for diabetes treatment, have gained popularity in the weight management market. In 2025, 11% of global consumers and 18% in the United States reported using these medications for weight loss. However, the use of GLP-1 is linked to side effects such as lean muscle loss, accounting for up to 40% of total weight lost, and gastric discomfort experienced by up to 76% of users.

To mitigate these challenges, Arla Foods Ingredients has developed high-protein concepts using ingredients like Nutrilac and Lacprodan BLG-100. These products aim to deliver essential amino acids for muscle health and include probiotics from Novonesis to support digestive well-being.

Anne Widart, Chief Commercial Officer of Arla Foods Ingredients, highlighted the growing demand for nutrient-dense, high-protein products suitable for smaller appetites among GLP-1 users. The company's new range includes a fermented high-protein shot offering 10g of protein per 70ml serving, a drinking yoghurt with 20g of protein per 200ml serving, and a high-protein water-based shot providing 21g of protein per 100ml serving.

Arla will also introduce two additional concepts at the event: an aerated protein bar solution and ready-to-stir medical nutrition powder solutions, further expanding their offerings for the dietary needs of GLP-1 medication users.